At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
A method for culturing the infectious stage of the Plasmodium lifecycle could increase malaria vaccine production efficiency by tenfold, study authors say.